Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer
Citations
2,945 citations
Cites background from "Therapeutic PD-1 Pathway Blockade A..."
...Both PD-L1 and L2 are regulated in TAMs and myeloid-derived suppressor cells (See below—MDSC) (Belai et al., 2014; Duraiswamy et al., 2013)....
[...]
1,690 citations
1,562 citations
Cites background from "Therapeutic PD-1 Pathway Blockade A..."
...Therapeutic blockade of immune checkpoints has been associated with a reversal in the distribution and proportion of MDSCs (8, 9)....
[...]
801 citations
663 citations
References
14,532 citations
4,795 citations
"Therapeutic PD-1 Pathway Blockade A..." refers background in this paper
...The role of Tregs in mediating immune suppression and tumor growth has been previously established in ovarian cancer (24, 31)....
[...]
4,431 citations
"Therapeutic PD-1 Pathway Blockade A..." refers background in this paper
...Tumors can use the PD-1 inhibitory pathway to silence the immune system (8)....
[...]
...PD-1 binds two ligands, programmed cell death ligand 1 (PD-L1) and PD-L2 called B7H1 and B7-DC, respectively (8, 9)....
[...]
4,109 citations
3,048 citations
"Therapeutic PD-1 Pathway Blockade A..." refers background or result in this paper
...Our finding of high frequency of Tregs in tumors lacking TILs is consistent with an association of Tregs with poor outcome in human ovarian cancer (4) and with the observation that, in these tumors, we found increased expression of vascular endothelial growth factor (4), which also correlates with Treg preponderance in the tumor microenvironment (31)....
[...]
...We have previously described the classification of ovarian cancers in tumors with and tumors without intraepithelial TILs (4)....
[...]